Johnson & Johnson
USUSDJohnson & Johnson (US:JNJ) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 3. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site web
- jnj.com
- Relations avec les investisseurs
- investor.jnj.com/overview/default.aspx
- Secteur
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siège social
- New Brunswick, United States
- PDG
- Joaquin Duato
- Employés
- 136 400
- Fondée
- 1886
- Actions en circulation
- Flottant
- 2.41 Md
- Capitalisation boursière
- 655.37 Md USD
- Initiés
- 0.05%
- Investisseurs institutionnels
- 76.73%
- Secteur d'activité (SIC)
- Pharmaceutical Preparations
- Forme juridique
- XSNP
- ISIN
- US4781601046
- LEI
- 549300G0CFPGEF6X2043
- Taux de distribution
- 60.0%
- FCF
- 22.2 Md USD57%
- Dette
- 49.0 Md USD1.3 ans de FCF
- Ancienneté du dividende
- 56+ ans
- Bénéfices, FCF et dividendes versés — pour les 12 mois précédant 30.06.2026 (le dernier rapport de l'entreprise).
Description
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Dividendes
Johnson & Johnson (JNJ) verse des dividendes trimestriels. Au cours des 12 derniers mois, 5.28 USD par action ont été versés (versements : 4). Cela représente environ 2.06% du cours actuel de l'action. D'après l'historique des paiements, la prochaine date ex-dividende est prévue vers 24.11.2026. Historique des dividendes ininterrompu : 56 ans.
| Date ex | Versement | Montant | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-08-25 | 2026-09-08 | 1.3400 USD | 0.5/2.1 % | trimestriel | US:JNJ |
| 2026-05-26 | 2026-06-09 | 1.3400 USD | 0.5/2.0 % | trimestriel | US:JNJ |
| 2026-02-24 | 2026-03-10 | 1.3000 USD | 0.5/2.0 % | trimestriel | US:JNJ |
| 2025-11-25 | 2025-12-09 | 1.3000 USD | 0.5/≈2.0 % | trimestriel | US:JNJ |
| 2025-08-26 | 2025-09-09 | 1.3000 USD | 0.5/≈2.0 % | trimestriel | US:JNJ |
| 2025-05-27 | 2025-06-10 | 1.3000 USD | 0.5/≈2.0 % | trimestriel | US:JNJ |
Actualités de cette semaine
Communiqués de presse du site de l'entreprise pour les investisseurs, mis à jour chaque jour. Les liens mènent au site de l'entreprise. Les titres sont dans la langue originale, comme sur le site web de l'entreprise.
Principaux actionnaires
| Détenteur | Participation | Actions | Date du rapport |
|---|---|---|---|
| BlackRock | 8.8% | 212.1 M | 2026-06-30 |
| Vanguard Capital Managem… | 6.52% | 157.23 M | 2026-06-30 |
| State Street Corporation | 5.55% | 133.78 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 76.42 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.67% | 64.37 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 62.38 M | 2026-06-30 |
| Geode Capital Management… | 2.45% | 59.09 M | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.42% | 58.3 M | 2026-06-30 |
| Morgan Stanley | 1.86% | 44.81 M | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 32.48 M | 2026-07-31 |
| NORGES BANK | 1.32% | 31.83 M | 2026-06-30 |
| State Farm Mutual Automo… | 1.31% | 31.59 M | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 31.13 M | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 29.45 M | 2026-08-31 |
| Northern Trust Corporati… | 1.19% | 28.79 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 22.91 M | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 17.3 M | 2026-08-31 |
| VANGUARD SPECIALIZED FUN… | 0.56% | 13.53 M | 2026-04-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 13.07 M | 2026-06-30 |
| VANGUARD WHITEHALL FUNDS… | 0.39% | 9.48 M | 2026-04-30 |
| DUATO JOAQUIN BOIX (Chie… | ≈0.01% | 307 837 | 2026-08-13 |
| TAUBERT JENNIFER L (Offi… | ≈0.01% | 194 451 | 2026-08-17 |
| WENGEL KATHRYN E (Chief… | ≈0% | 114 659 | 2026-06-11 |
| WOLK JOSEPH J (Chief Fin… | ≈0% | 85 008 | 2026-02-17 |
| SCHMID TIMOTHY (Officer) | ≈0% | 26 251 | 2026-09-02 |
| SWANSON JAMES D (Chief T… | ≈0% | 25 698 | 2026-02-17 |
| REED JOHN C (Officer) | ≈0% | 24 911 | 2026-05-01 |
| DECKER ROBERT J (Officer… | ≈0% | 24 462 | 2026-02-27 |
| BROADHURST VANESSA (Offi… | ≈0% | 23 003 | 2026-07-20 |
| MULHOLLAND KRISTEN (Offi… | ≈0% | 19 830 | 2026-02-13 |
| The Vanguard Group | — | — | — |
